Chemical synthesis and biological activity of a novel fluorescent etoposide derivative

Biochemical Pharmacology

Volumn 53, Issue 5, 1997, Pages 715-722

  Lazo, John S ^a,b   Li, Tianhu ^a,c   Woo, Elizabeth S ^a   Settineri, Catherine E ^a   Allan, William P ^a   Yalowich, Jack C ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

drug resistance; etoposide; fluorescent drug; topoisomerase; tumor cells

Indexed keywords

ETOPOSIDE; ETOPOSIDE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CROSS RESISTANCE; DNA BINDING; DRUG SYNTHESIS; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BORON COMPOUNDS; ETOPOSIDE; FLUORESCENCE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030936595     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00906-9     Document Type: Article

References (24)

1. Teicher BA, Drug Resistance in Oncology. Marcel Dekker, New York, 1993.
2. Liu L, DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-377, 1989.
3. Allen LM, Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4′-demethyl epipodophyllotoxin thenylidene-β-D-glucoside and 4′-demethyl epipodophyllotoxin ethylidene-β-D-glucoside, in the L1210 leukemia cell. Cancer Res 38: 2549-2554, 1978.
4. Sehested M, Friche E, Jensen PB and Demant EJF, Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res 52: 2874-2879, 1992.
5. Yalowich JC and Ross WE, Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res 45: 1651-1656, 1985.
6. Politi PM and Sinha BK, Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: Implications for the mechanisms of drug resistance. Mol Pharmacol 35: 271-278, 1989.
7. Long BH, Wang L, Lorico A, Wang RCC, Brattain MG and Casazza AM, Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51: 5275-5284, 1991.
8. 10b. Cancer Res 52: 709-718, 1992.
9. Lazo JS, Mistry JS and Sebti SM, Fluoromycin: A novel bleomycin analog. J Cell Pharmacol 3: 94-97, 1992.
10. Rusnak JM, Calmels TPG, Hoyt DG, Kondo Y, Yalowich JC and Lazo JS, Genesis of discrete higher order DNA fragments in apoptotic human prostate carcinoma cells. Mol Pharmacol 49: 244-252, 1996.
11. Lazo JS, Kondo Y, Dellapiazza D, Michalska AE, Choo KHA and Pitt BR, Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. J Biol Chem 270: 5506-5510, 1995.
12. Ritke MK and Yalowich JC, Altered gene expression in human leukemia K562 cells selected for resistance to etoposide (VP-16). Biochem Pharmacol 46: 2007-2020, 1993.
13. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV and Yalowich JC, Altered stability of etoposide-induced topoisomerase II/DNA complexes in resistant human leukemia K562 cells. Br J Cancer 69: 687-697, 1994.
14. Filipski J and Kohn KW, Ellipticine-induced protein-associated DNA breaks in isolated L1210 nuclei. Biochim Biophys Acta 698: 280-286, 1982.
15. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M and Blick M, Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 264: 16411-16420, 1989.
16. Stähelin HF and von Wartburg A, The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture. Cancer Res 51: 5-15, 1991.
17. Lelong IH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM and Willingham MC, Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. Mol Pharmocol 40: 490-494, 1991.
18. Yalowich JC, Lush RM, Allan WP, Rabindran S and Greenberger LM, Acquired resistance to etoposide in K562 cells: Multidrug resistance associated protein overexpression occurs subsequent to changes in DNA topoisomerase II. Proc Am Assoc Cancer Res 37: 2128, 1996.
19. Yalowich JC, Microtubule inhibitor effects on etoposide accumulation and DNA damage in human K562 leukemia cells in vitro. Cancer Res 47: 1010-1015, 1987.
20. Assaraf YG and Schimke RT, Identification of methotrexate transport deficiency in mammalain cells using fluoresceinated methotrexate and flow cytometry. Proc Natl Acad Sci USA 84: 7154-7158, 1987.
21. Stearns ME, Jenkins DP and Tew KD, Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natj Acad Sci USA 82: 8483-8487, 1985.
22. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM and Pastan I, Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effects of verapamil and other drugs. Cancer Res 46: 5941-5946, 1986.
23. Mistry JS, Koepsel RR and Lazo JS, Structural basis for the sequence selectivity of DNA cleavage by beomycins. Biochem Biophys Res Commun 191: 420-426, 1993.
24. Ross W, Rowe T, Glisson B, Yalowich J and Liu L, Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857-5860, 1984.